Monitor post-meeting filings for any share issuance or equity award grants under the new plan. The share authorization increase could precede a future capital raise.
SPRO drugs
SPRO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 28 $2.67entry
- T+1 · 7mo ago −4.87%α −4.86% · $2.54
- T+5 · 7mo ago −6.37%α −8.06% · $2.50
- T+20 · 6mo ago +7.12%α +1.65% · $2.86
- T+60 · 4mo ago −56.55%α −60.54% · $1.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spero Therapeutics filed additional proxy materials for its 2026 Annual Meeting, scheduled for June 23, 2026. Proposals include electing two Class III directors, ratifying the auditor, advisory vote on executive compensation, doubling authorized shares from 120M to 240M, and adopting a new stock incentive plan. The board recommends a 'For' vote on all items.
Key Financial Metrics
Key Facts
- Annual meeting set for June 23, 2026
- Proposal to increase authorized common shares from 120,000,000 to 240,000,000
- Proposal to adopt the 2026 Spero Therapeutics, Inc. Stock Incentive Plan
- All five proposals are recommended 'For' by the board
- Market cap ~$159M with mixed analyst consensus
Financial Impact
Potential dilution from doubling authorized shares, but no immediate issuance announced.
Risk Factors
- Future dilution from authorized share increase
- Potential overhang if new equity issuance is announced
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-182256 |
| Document: 0001193125-26-182256-index-headers.html | 0001193125-26-182256 |
| Document: 0001193125-26-182256-index.html | 0001193125-26-182256 |
| Document: 0001193125-26-182256.txt | 0001193125-26-182256 |
Track record
17 reports on SPRO
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
- Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
- Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
- Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
- Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers